Keratinocyte growth factor impairs human thymic recovery from lymphopenia

The lymphocyte-depleting antibody alemtuzumab is a highly effective treatment of relapsing-remitting multiple sclerosis (RRMS); however 50% of patients develop novel autoimmunity post-treatment. Most at risk are individuals who reconstitute their T-cell pool by proliferating residual cells, rather t...

Full description

Saved in:

Bibliographic Details
Published in:	JCI insight Vol. 4; no. 12
Main Authors:	Coles, Alasdair J., Azzopardi, Laura, Kousin-Ezewu, Onajite, Mullay, Harpreet Kaur, Thompson, Sara A.J., Jarvis, Lorna, Davies, Jessica, Howlett, Sarah, Rainbow, Daniel, Babar, Judith, Sadler, Timothy J., Brown, J. William L., Needham, Edward, May, Karen, Georgieva, Zoya G., Handel, Adam E., Maio, Stefano, Deadman, Mary, Rota, Ioanna, Holländer, Georg, Dawson, Sarah, Jayne, David, Seggewiss-Bernhardt, Ruth, Douek, Daniel C., Isaacs, John D., Jones, Joanne L.
Format:	Journal Article
Language:	English
Published:	United States American Society for Clinical Investigation 20.06.2019
Subjects:	Adolescent Adult Animals CD4-Positive T-Lymphocytes - immunology CD52 Antigen - metabolism Clinical Medicine Disease Models, Animal Female Fibroblast Growth Factor 7 - pharmacology Fibroblast Growth Factor 7 - therapeutic use Humans Lymphopenia - drug therapy Male Mice Middle Aged Multiple Sclerosis, Relapsing-Remitting - immunology Young Adult T cell development Immunology Autoimmune diseases T cells Therapeutics
ISSN:	2379-3708, 2379-3708
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!